Patent classifications
A61K31/047
Neuroblastoma treatment with taurolidine hydrolysis products
Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. The efficacy in rodent model is superior to the efficacy in cell culture. This invention relates to the use of taurolidine hydrolysis products (tarultam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in juvenile mammals.
COMPOSITIONS COMPRISING HYPER HARMONIZED HYDROXYL MODIFIED FULLERENE SUBSTANCES
The present invention relates to hyper harmonized hydroxyl-modified fullerenes, hydroxyl-modified fullerenes in a suitable carrier, and hydroxyl-modified fullerene formulations including a suitable carrier with optional additives. These compositions of matter and formulations have numerous applications including, for example, the cosmetic industry, dietary supplements, food industry, plants and healthcare fields.
COMPOSITIONS COMPRISING HYPER HARMONIZED HYDROXYL MODIFIED FULLERENE SUBSTANCES
The present invention relates to hyper harmonized hydroxyl-modified fullerenes, hydroxyl-modified fullerenes in a suitable carrier, and hydroxyl-modified fullerene formulations including a suitable carrier with optional additives. These compositions of matter and formulations have numerous applications including, for example, the cosmetic industry, dietary supplements, food industry, plants and healthcare fields.
Topical treatments incorporating <i>Cannabis </i>sp. derived botanical drug product
A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.
Topical treatments incorporating <i>Cannabis </i>sp. derived botanical drug product
A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.
Hair growth agent
The present invention is directed to a hair growth agent for external use comprising chiro-inositol, which is provided as an excellent hair growth agent.
Hair growth agent
The present invention is directed to a hair growth agent for external use comprising chiro-inositol, which is provided as an excellent hair growth agent.
COMPOSITION FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISORDERS
Provided is a composition useful for preventing and/or treating neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. The composition is for preventing and/or treating a neurodegenerative disorder, and contains, as an active ingredient, a compound represented by the following formula (I):
##STR00001##
or an isomer thereof, or a salt thereof.
COMPOSITION FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISORDERS
Provided is a composition useful for preventing and/or treating neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. The composition is for preventing and/or treating a neurodegenerative disorder, and contains, as an active ingredient, a compound represented by the following formula (I):
##STR00001##
or an isomer thereof, or a salt thereof.
MICROBIOME REGULATORS AND RELATED USES THEREOF
Compositions comprising microbiome regulators are provided, as well as methods of using the same for the modulation of the human microbiota and to treat or prevent related diseases, disorders, or conditions.